Back to results
US 2018/0021375 A1Published application
Modified blood clots
AssigneeNayacure Therapeutics Ltd.
InventorShahar COHEN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for preparing modified blood clots comprising removal of the cellular content of the blood clots. The invention further provides uses of the modified blood clots as therapeutic agents and as delivery vehicles for cells, bio-molecules and other agents.
Claims21
1-46. (canceled)
A method for preparing a modified blood clot comprising:
- (a) Obtaining a blood clot;
- and
- (b) Removing the cellular content of said blood clot;
- thereby obtaining a modified blood clot.
1 more element
A method of entrapping at least one agent within an insoluble biocompatible scaffold, said method comprising:
- (a) obtaining a blood clot;
- and
- (b) removing the cellular content of said blood clot;
- thereby obtaining a modified blood clot wherein said modified blood clot is characterized by being insoluble, biocompatible and comprising at least one agent entrapped therein.
1 more element
A modified blood clot wherein said modified blood clot is modified ex vivo and is characterized by one or more of the following:
- (a) stabilized with anti-fibrinolytic factors,
- (b) free or substantially free of cellular content,
- (c) incorporates biomolecules with antimicrobial activity,
- (d) incorporates activated platelets and activated WBC-derived biomolecules,
- (e) incorporates platelets and WBC activating factors, and
- (f) incorporates soluble serum biomolecules such as albumin.
3 more elements
Dependencies are inferred from the claim text.